APA (7th ed.) Citation

RJ, B., Y, L., EM, M., JJ, L., DB, C., A, A., . . . PR, S. (2025). Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: An open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. The Lancet. Neurology, 24(4), 316. https://doi.org/10.1016/S1474-4422(25)00024-9

Chicago Style (17th ed.) Citation

RJ, Bateman, et al. "Safety and Efficacy of Long-term Gantenerumab Treatment in Dominantly Inherited Alzheimer's Disease: An Open-label Extension of the Phase 2/3 Multicentre, Randomised, Double-blind, Placebo-controlled Platform DIAN-TU Trial." The Lancet. Neurology 24, no. 4 (2025): 316. https://doi.org/10.1016/S1474-4422(25)00024-9.

MLA (9th ed.) Citation

RJ, Bateman, et al. "Safety and Efficacy of Long-term Gantenerumab Treatment in Dominantly Inherited Alzheimer's Disease: An Open-label Extension of the Phase 2/3 Multicentre, Randomised, Double-blind, Placebo-controlled Platform DIAN-TU Trial." The Lancet. Neurology, vol. 24, no. 4, 2025, p. 316, https://doi.org/10.1016/S1474-4422(25)00024-9.